Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Multiple Sclerosis

  Free Subscription


2 Brain
1 J Immunol
2 J Neurol
7 Mult Scler
1 Neurology
1 Neurosci Lett
2 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles


  1. JOKUBAITIS VG, Campagna MP, Ibrahim O, Stankovich J, et al
    Not all roads lead to the immune system: the genetic basis of multiple sclerosis severity.
    Brain. 2022 Nov 30:awac449. doi: 10.1093.
    PubMed         Abstract available

    Location, location, location: myelin repair and proximity to ventricular CSF in multiple sclerosis.
    Brain. 2022 Nov 30:awac448. doi: 10.1093.

    J Immunol

  3. MATTER AL, Liggitt D, Goverman JM
    B Cells Drive MHC Class I-Restricted CD4 T Cells to Induce Spontaneous Central Nervous System Autoimmunity.
    J Immunol. 2022;209:1880-1891.
    PubMed         Abstract available

    J Neurol

  4. SIMPSON R, Posa S, Bruno T, Simpson S, et al
    Conceptualization, use, and outcomes associated with compassion in the care of people with multiple sclerosis: a scoping review.
    J Neurol. 2022 Nov 29. doi: 10.1007/s00415-022-11497.
    PubMed         Abstract available

  5. PREZIOSA P, Rocca MA, Pagani E, Valsasina P, et al
    Structural and functional magnetic resonance imaging correlates of fatigue and dual-task performance in progressive multiple sclerosis.
    J Neurol. 2022 Nov 27. doi: 10.1007/s00415-022-11486.
    PubMed         Abstract available

    Mult Scler

  6. HEGEN H, Walde J, Berek K, Arrambide G, et al
    Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A systematic review and meta-analysis.
    Mult Scler. 2022 Dec 1:13524585221134213. doi: 10.1177/13524585221134213.
    PubMed         Abstract available

  7. MOTTE J, Gold R
    Immune checkpoint inhibitors: A potential bright spot in the treatment of progressive multifocal leukoencephalopathy in multiple sclerosis.
    Mult Scler. 2022 Nov 30:13524585221137275. doi: 10.1177/13524585221137275.

  8. BARRITT AW, Das E, Morley N, Seymour M, et al
    Management approach including pembrolizumab for fingolimod-associated progressive multifocal leukoencephalopathy in a patient with relapsing-remitting multiple sclerosis.
    Mult Scler. 2022 Nov 30:13524585221137279. doi: 10.1177/13524585221137279.
    PubMed         Abstract available

  9. MORADI N, Sharmin S, Malpas CB, Shaygannejad V, et al
    External validation of a clinical prediction model in multiple sclerosis.
    Mult Scler. 2022 Nov 30:13524585221136036. doi: 10.1177/13524585221136036.
    PubMed         Abstract available

  10. Corrigendum for Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
    Mult Scler. 2022 Nov 30:13524585221138507. doi: 10.1177/13524585221138507.

  11. BARRO C, Healy BC, Saxena S, Glanz BI, et al
    Serum NfL but not GFAP predicts cognitive decline in active progressive multiple sclerosis patients.
    Mult Scler. 2022 Nov 30:13524585221137697. doi: 10.1177/13524585221137697.
    PubMed         Abstract available

  12. REDER AT, Stuve O, Tankou SK, Leist TP, et al
    T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy.
    Mult Scler. 2022 Nov 28:13524585221134216. doi: 10.1177/13524585221134216.
    PubMed         Abstract available


  13. KHAKBAN A, Llorian ER, Michaux KD, Patten SB, et al
    Direct Health Care Costs Associated With Multiple Sclerosis: A Population-Based Cohort Study From 2001 to 2020 in British Columbia, Canada.
    Neurology. 2022 Nov 30:10.1212/WNL.0000000000201645.
    PubMed         Abstract available

    Neurosci Lett

  14. SOHRABI P, Parnow A, Jalili C
    Treadmill aerobic training improve beam-walking test, up-regulate expression of main proteins of myelin and myelination in the hippocampus of cuprizone-fed mice.
    Neurosci Lett. 2023;792:136936.
    PubMed         Abstract available

    PLoS One

  15. YANG B, Parker RB, Meibohm B, Temrikar ZH, et al
    Alcohol inhibits the metabolism of dimethyl fumarate to the active metabolite responsible for decreasing relapse frequency in the treatment of multiple sclerosis.
    PLoS One. 2022;17:e0278111.
    PubMed         Abstract available

  16. VALORI M, Lehikoinen J, Jansson L, Clancy J, et al
    High prevalence of low-allele-fraction somatic mutations in STAT3 in peripheral blood CD8+ cells in multiple sclerosis patients and controls.
    PLoS One. 2022;17:e0278245.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.